Latest Merger And Acquisition News

Northern Star Resources acknowledges Elliott Investment Management's views and reiterates its focus on leadership succession, project milestones, and strategic corporate reviews.

Bremworth's acquisition by Floorscape faces further delay as the New Zealand Commerce Commission extends its clearance deadline to 30 June 2026, pushing the deal close to its expiry date.

IPD Group signals a strong FY26 with EBITDA guidance up 18% and robust revenue growth, underpinned by acquisition integration and operational efficiencies.

Parkway Corporate has teamed up with Hitachi to develop modular ultra-high brine concentration systems, crucial for its flagship Queensland Brine Management Complex project aimed at transforming industrial waste brine into green chemicals.

REA Group delivered robust Q3 FY26 results, driven by double-digit revenue growth in Australia and record engagement on realestate.com.au, while lowering its cost growth guidance for FY26.

Amaero Ltd is set to re-domicile from Australia to Delaware via court-approved schemes, issuing US HoldCo CHESS Depositary Interests to shareholders while maintaining its ASX listing. The move aims to tap into deeper US capital markets and enhance strategic growth opportunities.

Decidr AI Industries has successfully completed a $15 million placement to fund key product development and expansion initiatives, reinforcing its lead in the agentic AI sector.

Kingsrose Mining has appointed Andrew Caruso as its new CEO, bringing over three decades of mining leadership experience to drive its Scandinavian projects and acquisition strategy. His remuneration package includes a base salary of CND$400,000 plus performance-linked incentives tied to share price milestones.

Regal Partners showcased its diversified $21 billion funds under management and ongoing growth momentum at the Macquarie Australia Conference, emphasising strong inflows, product innovation, and offshore expansion.

Ampol Limited showcased resilience in 2025 with strong refining margins supported by government payments and robust retail growth, while awaiting ACCC approval for its EG Australia acquisition promising significant synergies.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.